1. FDA designates long-acting PrEP a breakthrough therapy  Healio
  2. ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention  Business Wire
  3. View Full coverage on Google News
The FDA has granted breakthrough therapy designation status to long-acting, injectable cabotegravir for HIV PrEP, according to ViiV Healthcare. The updated designation is based on results from the HIV Prevention Trials Network 083 study (HPTN 083), which showed that transgender women and men who have sex with men who were taking injectable cabotegravir were 66% less likely to acquire HIV than The FDA has granted breakthrough therapy designation status to long-acting, injectable cabotegravir for HIV PrEP, according to ViiV Healthcare. The updated designation is based on results from the HIV Prevention Trials Network 083 study (HPTN 083), which showed that transgender women and men who have sex with men who were taking injectable cabotegravir were 66% less likely to acquire HIV than

FDA designates long-acting PrEP a breakthrough therapy

ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV preventionViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention | Business Wire